The OHE has released a Discussion Paper on indication based-pricing which is open for consultation until 24th June 2019.
The Office of Health Economics (OHE) released a Discussion Paper on 10th May 2019 detailing the advantages and disadvantages of indication-based pricing, as it attempts to innovate drug payment mechanisms to bring them into line with industry developments.
‘Although the science underlying the way in which medicines are developed has evolved, there has been little change in how we pay for them. Increasingly, medicines will have multiple indications. New payment mechanisms are being proposed to better align reimbursement policies with the innovation landscape.’
– OHE press release
The Discussion Paper is out for consultation until Monday 24th June 2019, and input from interested stakeholders is strongly encouraged.